NASDAQ: FTHFaeth Therapeutics Inc Stock
$16.65+2.12 (+14.59%)
Updated Jun 17, 2026
FTH Price
$16.65
Fair Value Price
$5.68
Market Cap
$22.34M
52 Week Low
$6.33
52 Week High
$36.76
P/E
-0.12x
P/B
-0.16x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$184.46M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.1
Operating Cash Flow
-$24M
Beta
1.03
Next Earnings
Aug 4, 2026
Ex-Dividend
N/A
Next Dividend
N/A
FTH Overview
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FTH's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
FTH
Ranked#409 of 463
Ranked#409 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.93 | A | |
| $52.44 | A | |
| $16.14 | A |
Be the first to know about important FTH news, forecast changes, insider trades & much more!
FTH News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FTH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FTH ($16.65) is overvalued by 193.22% relative to our estimate of its Fair Value price of $5.68 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
FTH ($16.65) is not significantly undervalued (193.22%) relative to our estimate of its Fair Value price of $5.68 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
FTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FTH due diligence checks available for Premium users.
Valuation
FTH fair value
Fair Value of FTH stock based on Discounted Cash Flow (DCF)
Price
$16.65
Fair Value
$5.68
Overvalued by
193.22%
FTH ($16.65) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FTH ($16.65) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FTH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
14.91x
Market
12.4x
FTH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.16x
Industry
4.94x
FTH's financial health
Profit margin
Revenue
$0.0
Net Income
-$170.2M
Profit Margin
0%
FTH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$205.4M
Liabilities
$14.2M
Debt to equity
-0.1
FTH's short-term assets ($204.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FTH's short-term assets ($204.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FTH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FTH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.7M
Investing
-$31.4M
Financing
$185.8M
FTH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FTH vs Biotech Stocks
Faeth Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.